Metformin's Impact on Rectal Cancer: New Research Reveals Promising Findings

A new study from Chang Gung Memorial Hospital Linkou in Taoyuan, Taiwan, has shed light on the effects of metformin on rectal cancer patients undergoing neoadjuvant chemoradiotherapy. The research, published in Scientific Reports, involved a retrospective analysis of 89 patients with locally advanced rectal cancer, of whom 56 were metformin users and 33 were non-users. The study found that metformin users demonstrated significantly improved tumor regression grade (p = 0.006), suggesting a potential association between metformin dosage and treatment response. However, no significant difference was observed in overall survival or disease-free survival between the two groups.

Key Takeaways:

• The study involved a retrospective analysis of 89 patients with locally advanced rectal cancer, of whom 56 were metformin users and 33 were non-users.
• Metformin users demonstrated significantly improved tumor regression grade (p = 0.006), suggesting a potential association between metformin dosage and treatment response.
• No significant difference was observed in overall survival or disease-free survival between the two groups.
• The study suggests that metformin may influence the response to neoadjuvant chemoradiotherapy in rectal cancer patients.
• Further research is warranted to validate these findings and explore the optimal metformin dosage and treatment regimens.
• The research was conducted at Chang Gung Memorial Hospital Linkou, a major hospital in Taoyuan, Taiwan.
• The study involved a collaboration between researchers from various departments, including surgery, oncology, and endocrinology.

Statistics:

• 89 patients were included in the study, of whom 56 were metformin users and 33 were non-users.
• Metformin users demonstrated a significantly improved tumor regression grade, with a p-value of 0.006.
• No significant difference was observed in overall survival, with a p-value of 0.42.
• No significant difference was observed in disease-free survival, with a p-value of 0.31.
• The study involved a retrospective analysis of patients treated between January 2005 and December 2019.

Sources:

• Scientific Reports. Metformin's Impact On Tumor Regression Grade In Diabetic Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy.
• Chang Gung Memorial Hospital Linkou.
• Nature Publishing Group. Scientific Reports.
• NewsRx. Researchers from Chang Gung Memorial Hospital Linkou Describe Findings in Rectal Cancer (Metformin's Impact On Tumor Regression Grade In Diabetic Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy). Cancer Weekly. August 19, 2025; p 472.